Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Immunology
  •  Gastrointestinal Cancer
  •  Kidney Cancer
  •  Urological Cancers
  •  Radiation Oncology
  •  Ovarian Cancer
  •  Hematology
  •  Colorectal Cancer

Abstract

Citation: Clin Oncol. 2016;1(1):1018.DOI: 10.25107/2474-1663.1018

Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma Demographics, Prognosis, and Staging

Ryan K. Cleary and Anthony J. Cmelak

Department of Radiation Oncology, Vanderbilt University Medical Center, USA

*Correspondance to: Anthony J. Cmelak 

 PDF  Full Text Review Article | Open Access

Abstract:

Human papillomavirus (HPV) is a sexually-transmitted infection that is responsible for increasing rates of oropharyngeal squamous cell carcinoma (OPSCC) in the United States and around the world. Compared to head and heck squamous cell carcinomas (HNSCC) caused by traditional risk factors such as smoking and alcohol, patients with HPV-positive (HPV+) OPSCC are younger, more likely to be male, and enjoy a significantly improved prognosis. As HPV status represents the most important prognostic variable for OPSCC patients, current staging systems which do not take it into account are inadequate for staging HPV+ OPSCC. Herein, we will review the shifting demographics of HPV infection as they relate to OPSCC incidence, outline the data suggesting improved outcomes in HPV+ OPSCC, and highlight current efforts to develop a new staging system for HPV+ OPSCC patients.

Keywords:

Cite the Article:

Cleary RK, Cmelak AJ. Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma Demographics, Prognosis, and Staging. Clin Oncol. 2016; 1: 1018.

Search Our Journal

Journal Indexed In

Articles in PubMed

NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Erlotinib Treatment Beyond Progression in EGFR Mutant Patients Who Have Responded to EGFR TKIs in Stage IIIB/IV NSCLC: An Open Label Randomized Trial
 Abstract  PDF  Full Text
Percutaneous Cryoablation for Clinical Stage I Non-Small Cell Lung Cancer: Histology, Results, and Safety
 Abstract  PDF  Full Text
View More...